Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017-2020

Wei-Ting Chen,Wing Hong Seto,Margaret Ip,Katherine Young,James A. Karlowsky,Sibylle H. Lob,Tsz K. Khan,Patrick C.Y. Woo,Stanley W.M. Leung,Queenie W.-L. Wong,Rene W.Y. Chau,C. Andrew DeRyke,Mary R. Motyl,Daniel F. Sahm
DOI: https://doi.org/10.1016/j.jgar.2023.04.004
IF: 4.349
2023-04-23
Journal of Global Antimicrobial Resistance
Abstract:Objectives To estimate carbapenem resistance in Pseudomonas aeruginosa and Enterobacterales isolated from infected patients in intensive-care unit (ICU) and non-ICU hospital wards in Hong Kong. Methods Isolates of P. aeruginosa (ICU, n =35; non-ICU, n =264) and Enterobacterales (ICU, n =129; non-ICU, n =1390) were collected in four Hong Kong hospitals in 2017-2020. CLSI broth microdilution MICs were interpreted by CLSI 2021 M100 breakpoints. β-lactamase genes were identified in imipenem-, imipenem/relebactam-, and ceftolozane/tazobactam-non-susceptible isolates. Results Ceftolozane/tazobactam demonstrated potent in vitro activity against both P. aeruginosa (ICU, 88.6%; non-ICU, 98.5%) and Enterobacterales (96.1% susceptible; 97.1%). Percent susceptible values for P. aeruginosa isolates from ICU and non-ICU patients were: meropenem (ICU, 74.3%; non-ICU, 84.1%) and imipenem (68.6%; 73.1%). Only one of 77 isolates tested for β-lactamase genes carried a carbapenemase (VIM-2). Percent susceptible values for Enterobacterales isolates from ICU and non-ICU patients were: meropenem (100%; 99.4%), ertapenem (100%; 98.0%), and imipenem (88.4%; 88.6%). 62 Enterobacterales isolates were tested for β-lactamase genes. Only three isolates carried a carbapenemase gene; two (both Escherichia coli ) were metallo-β-lactamase-positive (both NDM-5) and one ( Klebsiella pneumoniae ) was OXA-48-like-positive. Conclusions Carbapenem-nonsusceptible isolates of P. aeruginosa were common (>15% of isolates). P. aeruginosa percent susceptible values to ceftolozane/tazobactam (97.3% susceptible overall) were ≥14% higher than carbapenems for both ICU and non-ICU isolates. Carbapenemases were rare among both P. aeruginosa (one isolate) and Enterobacterales (three isolates). Most Enterobacterales isolates tested from ICU and non-ICU patients in Hong Kong hospitals in 2017-2020 were susceptible to meropenem and ertapenem (≥98%); imipenem was less active (89% susceptible).
pharmacology & pharmacy,infectious diseases
What problem does this paper attempt to address?